- Home
- NURO
NURO
NeuroMetrix Inc.
as 12-18-2024 1:40pm EST
NeuroMetrix Inc is a commercial-stage healthcare company. Its core business activities are integrated with in-house capabilities spanning product development, manufacturing, regulatory affairs and compliance, sales and marketing, and customer support. The company produces bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The product line of the company includes Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. The company operates in a single segment being Medical equipment and consumables.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 7.6M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 10.4K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.39 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.66 - $4.73 | Next Earning Date: | 11-05-2024 |
| Revenue: | $3,767,764 | Revenue Growth: | -41.41% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest NeuroMetrix Inc. News
NURO Breaking Stock News: Dive into NURO Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
electroCore to Acquire NeuroMetrix to Become Diversified Player in Non-Invasive Wellness Treatments
GlobeNewswire
a day ago
NeuroMetrix to be Acquired by electroCore
Zacks
a month ago
NeuroMetrix Q3 Loss Narrows Y/Y, Quell Sales Drives Growth
Simply Wall St.
a month ago
NeuroMetrix Third Quarter 2024 Earnings: US$0.75 loss per share (vs US$1.66 loss in 3Q 2023)
GlobeNewswire
a month ago
NeuroMetrix Reports Q3 2024 Business Highlights
MT Newswires
4 months ago
NeuroMetrix Finds No Viable Transactions in Strategic Review
GlobeNewswire
4 months ago
NeuroMetrix Reiterates its Review of Strategic Alternatives
Simply Wall St.
4 months ago
NeuroMetrix Second Quarter 2024 Earnings: US$0.75 loss per share (vs US$1.56 loss in 2Q 2023)
Compare NURO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NURO NeuroMetrix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.